Principles and practice of nonpharmacological interventions to reduce cardiometabolic risk

Medical Principles and Practice

Volumn 19, Issue 3, 2010, Pages 167-175

  Dagogo Jack, Samuel ^a   Egbuonu, Nonso ^a   Edeoga, Chimaroke ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Community prevention; Diet; Exercise; Prediabetes; Smoking cessation

Indexed keywords

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; CASE MANAGER; CEREBROVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DIABETES MELLITUS; DIETARY INTAKE; EPIGENETICS; EXERCISE; HEALTH BEHAVIOR; HEALTH EDUCATION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; MEDICAL PRACTICE; MENTAL STRESS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PRIMARY PREVENTION; REVIEW; RISK REDUCTION; SELF MONITORING; STRESS MANAGEMENT;

BODY WEIGHT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIET; EXERCISE; HEALTH BEHAVIOR; HUMANS; LIFE STYLE; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SMOKING CESSATION; STRESS, PSYCHOLOGICAL;

EID: 77950544263     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000285280     Document Type: Review

References (42)

1. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2009; 32(suppl 1):S62-S67.
2. Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, Claude JR, Rosselin GE: Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study, ten years later. Horm Metab Res 1985; 15(suppl):41-46.
3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412. (Pubitemid 30609442)
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
5. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359. (Pubitemid 34251969)
6. Ridker PM, Buring JE, Cook NR, Rifai N: Creactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003; 107: 391-397.
7. Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-342. (Pubitemid 38101606)
8. DCCT/EDIC Research Group: Intensive diabetes treatment and cardiovascular disease in type 1 diabetes in the DCCT/EDIC. N Engl J Med 2005; 353: 2643-2653. (Pubitemid 41817713)
9. Dagogo-Jack S: Primary prevention of cardiovascular disease in diabetic patients. Cardiol Q 2006; 12: 20-25.
10. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N: Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141: 413-420. (Pubitemid 39281877)
11. Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559. (Pubitemid 351831356)
12. ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572-12559 (Pubitemid 351831357)
13. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, VADT Investigators: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
14. Miyatake N, Wada J, Kawasaki Y, Nishii K, Makino H, Numata T: Relationship between metabolic syndrome and cigarette smoking in the Japanese population. Intern Med 2006; 45: 1039-1043. (Pubitemid 44613582)
15. Facchini FS, Hollenbeck CB, Jeppesen J, Chen YD, Reaven GM: Insulin resistance and cigarette smoking. Lancet 1992; 339: 1128-1130.
16. Heitzer T, Yla-Herttuala S, Luoma J, Kurz S, Munzel T, Just H, Olschewski M, Drexler H: Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia: role of oxidized LDL. Circulation 1996; 9: 1346-1353. (Pubitemid 126425255)
17. Kong C, Nimmo L, Elatrozy T, Anyaoku V, Hughes C, Robinson S, Richmond W, Elkeles RS: Smoking is associated with increased hepatic lipase activity, insulin resistance, dyslipidaemia and early atherosclerosis in type 2 diabetes. Atherosclerosis 2001; 156: 373-378. (Pubitemid 32522918)
18. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-544.
19. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350. (Pubitemid 32378388)
20. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403. (Pubitemid 34437694)
21. Diabetes Prevention Program Research Group: Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 2005; 28: 888-894. (Pubitemid 40434491)
22. Dagogo-Jack S: Primary prevention of cardiovascular disease in pre-diabetes: the glass is half-full and half-empty (editorial). Diabetes Care 2005; 28: 971-972. (Pubitemid 40434508)
23. Kubaszek A, Pihlajamaki J, Komarovski V, Lindi V, Lindstrom J, Eriksson J, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M, Finnish Diabetes Prevention Study Group: Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 2003; 52: 1872-1876.
24. Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, Knowler WC, Nathan DM, Altshuler D, Diabetes Prevention Program Research Group: TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006; 355: 241-250. (Pubitemid 44079339)
25. Moore AF, Jablonski KA, Mason CC, Mc- Ateer JB, Arakaki RF, Goldstein BJ, Kahn SE, Kitabchi AE, Hanson RL, Knowler WC, Florez JC, Diabetes Prevention Program Research Group: The association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the diabetes prevention program. J Clin Endocrinol Metab 2009; 94: 449-455.
26. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A, Styrkarsdottir U, Magnusson KP, Walters GB, Palsdottir E, Jonsdottir T, Gudmundsdottir T, Gylfason A, Samundsdottir J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thorsteinsdottir U, Gulcher JR, Kong A, Stefansson K: Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38: 320-323. (Pubitemid 43315754)
27. Abate N, Chandalia M, Satija P, Adams-Huet B, Grundy SM, Sandeep S, Radha V, Deepa R, Mohan V: ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes. Diabetes 2005; 54: 1207-1213. (Pubitemid 40446338)
28. Diabetes Prevention Program Research Group: The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program. Diabetologia 2007; 50: 2451-2460.
29. Florez JC, Jablonski KA, Sun MW, Bayley N, Kahn SE, Shamoon H, Hamman RF, Knowler WC, Nathan DM, Altshuler D, Diabetes Prevention Program Research Group: Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab 2007; 92: 1502-1509. (Pubitemid 46556431)
30. Kriska A: Striving for a more active community: lessons from the Diabetes Prevention Program and beyond. Am J Prev Med 2002; 22: 6-7. (Pubitemid 34436881)
31. Zimmet P, Shaw J, Alberti KGMM: Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet Med 2003; 20: 693-702. (Pubitemid 41701460)
32. Dagogo-Jack S, Askari H, Tykodi G: Glucoregulatory physiology in subjects with lownormal, high-normal, or impaired fasting glucose. J Clin Endocrinol Metab 2009; 94: 2031-2036.
33. Pan WH, Flegal KM, Chang HY, Yeh WT, Yeh CJ, Lee WC: Body mass index and obesity- related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians. Am J Clin Nutr 2004; 79: 31-39.
34. Kimm SY, Glynn NW, Kriska AM, Barton BA, Kronsberg SS, Daniels SR, Crawford PB, Sabry ZI, Liu K: Decline in physical activity in black and white girls during adolescence. N Engl J Med 2002; 347: 709-715. (Pubitemid 35203901)
35. Diabetes Prevention Program Research Group: The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002; 25: 2165-2171.
36. Esposito K, Pontillo A, di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D: Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289: 1799-1804. (Pubitemid 37430249)
37. Butryn ML, Phelan S, Hill JO, Wing RR: Consistent self-monitoring of weight: a key component of successful weight loss maintenance. Obesity (Silver Spring) 2007; 15: 3091-3096. (Pubitemid 351256672)
38. Diabetes Prevention Program Research Group: Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care 2003; 26: 977-980.
39. Look AHEAD Research Group: Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 2007; 30: 1374-1383.
40. Dagogo-Jack S: Primary prevention of type 2 diabetes in developing countries. J Natl Med Assoc 2006; 98: 415-419. (Pubitemid 43352534)
41. Collins SM: Legislative perspectives on diabetes in America. Endocr Pract 2002; 8(suppl 1):17-18.
42. Ackermann RT, Finch EA, Brizendine E, Zhou H, Marrero DG: Translating the Diabetes Prevention Program into the community: the DEPLOY Pilot Study. Am J Prev Med 2008; 35: 357-363.